Mark E. Robson, MD

Mark E. Robson, MD, discusses the potential utility of tucatinib in the treatment of patients with HER2-positive breast cancer.

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the application of precision medicine in breast cancer.

Mark E. Robson, MD, discusses the importance of educational efforts aimed at understanding the differences between biosimilars and biologics in oncology.

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the driving force behind biosimilar use in oncology.

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the toxicity profile of olaparib (Lynparza) in breast cancer.

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses an exploratory analysis of the OlympiAD trial for patients with HER2-negative breast cancer with a germline BRCA1/2 mutation.